KPT330 promotes the sensitivity of glioblastoma to olaparib by retaining SQSTM1 in the nucleus and disrupting lysosomal function-Reference-Cited by-全球学者库

KPT330 promotes the sensitivity of glioblastoma to olaparib by retaining SQSTM1 in the nucleus and disrupting lysosomal function

Published:2023-09-25 Issue:2 Volume:20 Page:295-310
ISSN:1554-8627
Container-title:Autophagy
language:en
Short-container-title:Autophagy

Author:

Wang Li-Hong¹²,Wei Sen²,Yuan Ye²,Zhong Ming-Jun³,Wang Jiao²,Yan Ze-Xuan²,Zhou Kai⁴,Luo Tao²,Liang Li¹,Bian Xiu-Wu²^ORCID

Affiliation:

1. Department of Pathology, School of Basic Medical Science, Southern Medical University, Guangzhou, Guangdong, China

2. Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University) and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing 400038, China

3. Institute of Rare Diseases, West China Hospital of Sichuan University, Chengdu 610000, China

4. Department of General Surgery and Center of Minimal Invasive Gastrointestinal Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China

Funder

General Project of Chongqing Natural Science Foundation

Special project of Scientific and Technological Innovation Capability Improvement of Army Military Medical University

Publisher

Informa UK Limited

Subject

Cell Biology,Molecular Biology

Link

https://www.tandfonline.com/doi/pdf/10.1080/15548627.2023.2252301

Reference75 articles.

1. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015

2. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair

3. Role of poly(ADP-ribose) formation in DNA repair

4. PARP inhibitors: Synthetic lethality in the clinic

5. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial